Diabetes complications and comorbidities: Neuropathy

The integrated results of the CANVAS and CANVAS-R studies show that canagliflozin reduces the risk for cardiovascular and renal events in patients with type 2 diabetes at high cardiovascular risk.

A meta-analysis from the Collaborators on Trials of Lowering Glucose group supports intensive glycemic control for improved microvascular outcomes in patients with type 2 diabetes.

The authors of a meta-analysis report mostly weak evidence, short-term follow-up, and evidence of publication bias in studies of pain relief in patients with diabetic peripheral neuropathy.

Researchers have found that people’s own perception of unsteadiness matches objective measures of balance and gait, making it a good indicator of fall risk in patients with diabetic peripheral neuropathy.

Research shows that the largest long-term reductions in microvascular complications around 20 years after bariatric surgery for obesity are seen among patients who had prediabetes at the time of surgery.

Nearly 2 decades after the launch of the Steno-2 study, patients with complicated diabetes given intensive multifactorial treatment have gained nearly 8 years of life, say the researchers.